From Surf Wiki (app.surf) — the open knowledge base

Porfimer sodium

Pharmaceutical drug

| Drugs.com =

| elimination_half-life = 21.5 days (mean)

Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.

Porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units. In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers.

Porfimer is Haematoporphyrin Derivative (HpD) (See PDT).

Approvals and indications

It was approved in Canada in 1993 for the treatment of bladder cancer. It was approved in Japan in 1994 (for early stage lung cancer?). It was approved by the U.S. FDA in December 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer.

In August 2003 the FDA approved its use for Barrett's esophagus.

References

"Porfimer injection Prescribing information".
(June 2006). "Photodynamic therapy (PDT) for lung cancers". Journal of Thoracic Oncology.
(October 2003). "FDA Patient Safety News: Show #20, October 2003".

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

photosensitizing-agents porphyrins

Want to explore this topic further?

Ask Mako anything about Porfimer sodium — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report